Agents Used in Antiretroviral Therapy

  • Authors: Philip Grant, MD (More Info)
  • Editors in Chief: Daniel R. Kuritzkes, MD; Joseph J. Eron, Jr., MD
  • Last Reviewed: 7/19/21 (What's New)

References

Abdool Karim Q, Abdool Karim SS, Frohlich JA, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science. 2010;329:1168-1174.[Abdool Karim 2010]

Arastéh K, Ward D, Plettenberg A, et al. 48-week efficacy and safety of transitioning virologically stable HIV-1 patients from nevirapine IR 200 mg BID to nevirapine XR 400 mg QD (TRANxITION). Programs and abstracts of the Tenth International Congress on Drug Therapy in HIV Infection; November 7-11, 2010; Glasgow, United Kingdom. Abstract P45.[Arastéh 2010]

Arenas-Pinto A, Grund B, Sharma S, et al. Increased risk of suicidal behaviour with use of efavirenz: Results from the START trial. Program and abstracts of the 21st International AIDS Conference; July 18-22, 2016; Durban, South Africa. Abstract THAB0202.[Arenas-Pinto 2016]

...

Action required

Keywords: Initial Antiretroviral Therapy, Special Populations, Treatment Complications

©2020 Clinical Care Options, LLC. All Rights Reserved.

The materials published via inPractice® reflect the views of the reviewers or authors of the material, not those of Clinical Care Options, LLC, the accredited provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.